Wordt geladen...

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

The combination of targeted therapy with BRAF and MEK inhibitors has become the standard of care in patients with BRAF(V600E) mutant melanoma, but responses are not durable. In addition, the impressive clinical benefits with anti-PD-1 and anti-PD-L1 antibodies (Ab) in patients with heavily pretreate...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncoimmunology
Hoofdauteurs: Homet Moreno, Blanca, Mok, Stephen, Comin-Anduix, Begonya, Hu-Lieskovan, Siwen, Ribas, Antoni
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Taylor & Francis 2015
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006894/
https://ncbi.nlm.nih.gov/pubmed/27622011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1052212
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!